GenPo Science All articles
Clinical Genetics

The Second Test Problem: Who Pays When a Genetic Result Needs Confirmation

GenPo Science
The Second Test Problem: Who Pays When a Genetic Result Needs Confirmation

Photo by Photo by Vitaly Gariev on Unsplash on Unsplash

A genetic test result can look like an ending. A variant is flagged, a report is signed, and a patient leaves the clinic with a name for what had been uncertain. In practice, that first result is often a beginning. Clinical laboratories may need a second method to confirm a finding, parents may need to be tested to interpret a child's variant, and relatives may need cascade screening to learn whether the same change runs through the family. Each step has a price, a billing pathway, and a coverage rule. Few of those steps are visible when the first test is ordered.

A Result Is Not Always an Answer

Genomic testing has become more efficient, but efficiency has not eliminated the need for confirmation. A laboratory may detect a variant with one platform and confirm it with another, especially when the finding will guide surgery, medication, or reproductive decisions. Parental testing can clarify whether a variant is inherited or newly arisen. Cascade screening can turn one result into a family-wide search. These are not optional extras in a well-run clinical program. They are part of the diagnostic process.

The financial design of American health care, however, tends to treat the first test as the main event. Prior authorization may be built around the initial order. Coverage policies may specify which test is payable, for which indication, and by which laboratory. The confirmatory step can arrive later, often after the clinical team has already acted on a provisional interpretation. Patients may discover that the second test is considered separately, and sometimes less favorably, than the first.

The Billing Trail Behind a Single Variant

A single finding can generate a surprisingly long billing trail. There may be a laboratory charge for confirmation, a professional charge for interpretation, a separate charge for parental testing, and additional costs for genetic counseling. If the patient is a child, the family may face coordination across pediatric and adult coverage rules. If the finding affects relatives, cascade screening may require yet more orders and more prior authorizations.

For patients, the result is not merely a bill. It is a second round of waiting, a new set of forms, and sometimes a difficult conversation about who in the family should be tested first. For laboratories, the work can be equally awkward. Confirmatory testing often involves labor-intensive review, custom assay design, or repeat analysis that is poorly captured by standard payment models. Small academic and nonprofit laboratories may absorb some of that cost because the clinical question is urgent and the patient is already in front of them. That is not a sustainable business model.

Why Confirmation Costs More Than It Looks

The hidden costs are not only financial. A confirmatory test can delay a final diagnosis, which in turn delays treatment planning, reproductive decision-making, and family communication. Genetic counselors may spend additional sessions explaining why a result is being checked, what the second test can and cannot prove, and what the patient should tell relatives in the meantime. Those sessions are clinical work, but they are not always reimbursed as such.

There is also an equity dimension. Patients with generous insurance, stable employment, and access to academic centers may move through confirmatory testing with relative ease. Patients with high-deductible plans, Medicaid coverage that varies by state, or limited access to specialty genetics may face a different reality. A second test that is clinically routine can become a financial decision. When that happens, the health system is effectively asking patients to weigh diagnostic certainty against household budget.

Counseling Before the Invoice

Patient counseling should prepare people for the possibility that one test will lead to another. That means explaining, in plain language, why confirmation matters, which family members may need testing, and what the patient may be asked to pay. It also means giving patients a realistic sense of timing. A result that requires parental testing is not a result that can always be interpreted in a week.

Clinicians and laboratories should also document the rationale for confirmatory testing clearly. Payers need to see that the second test is not duplicative but clinically necessary. A well-written order and a clear laboratory note can make the difference between smooth coverage and a prolonged appeal. That is not glamorous work, but it is part of responsible genomic medicine.

A Policy Gap With Clinical Consequences

Insurance policy has not kept pace with the sequential nature of genomic diagnosis. Coverage rules often focus on the initial test and treat downstream testing as a separate administrative event. A more coherent approach would recognize confirmatory testing, parental studies, and cascade screening as parts of a single diagnostic episode. It would also create clearer pathways for reimbursement when a laboratory must repeat or extend an analysis to reach a clinically actionable answer.

None of this argues for unlimited testing. It argues for honest accounting. If genomic medicine is going to deliver on its promise, the system must pay for the steps that make a result trustworthy. The second test is not an afterthought. It is often where the real diagnostic work begins.

All Articles

Related Articles

Written Before the Test: Why American Prescriptions Still Ignore Pharmacogenomic Evidence

Written Before the Test: Why American Prescriptions Still Ignore Pharmacogenomic Evidence

The Bottleneck Behind the Breakthrough: America's Genetic Counselor Shortage

The Bottleneck Behind the Breakthrough: America's Genetic Counselor Shortage

Custodians of Ourselves: Tracing What Really Happens to Donated DNA When Institutions Change Hands

Custodians of Ourselves: Tracing What Really Happens to Donated DNA When Institutions Change Hands